Sinem SAĞ

Frequency of depression, anxiety, and fatıgue in fmf patients and their association with disease parameters

The aim of our study was to assess the levels of depression, anxiety, and fatigue in patients diagnosed with FMF (Familial Mediterranean Fever) and to examine their associations with drug compliance, attack, and being employed or not. Patients presenting to our rheumatology outpatient clinic Tel-Hashomer Classification Criteria were included in the study. Fifty-two diagnosed patients followed up in our rheumatology outpatient clinic (35 female, 17 male), and 30 healthy control subjects whose ages and genders match consisting of the accompanists and visitors of the patients (25 female, 5 male) were included. Risk for depression and anxiety was assessed with HADS (Hospital Anxiety and Depression Scale). Depression and anxiety were observed to be significantly more common in the patients with FMF compared to the healthy controls in this study. Also, the frequency of FMF attacks was found to be associated with depression, anxiety, and fatigue and that regular use of colchicine decreased fatigue. In the light of all these results, the mood should definitely be evaluated during the routine practice in case of a chronic disease such as FMF having a younger patient population compared to other rheumatic diseases, and, if needed, psychiatric support should be received. Also, it should be explained to the patients that the regular use of colchicine would be beneficial for both the disease and fatigue. There is a need for follow-up studies with large case series in order to support the results we obtained.

PDF

___

Firestein GS, Budd R, Gabriel SE, et al. Kelley’s textbook of rheumatology. Elsevier Health Sciences, 2012, Philadelphia.

Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial mediterranean fever. Arthr Rheum. 1997;10:1879-85.

Consortium TIF. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial mediterranean Fever. Cell. 1997;90:797-807.

Consortium FF. A candidate gene for familial mediterranean Fever. Nat Genet. 1997;171:25-31.

Chae J, Wood G, Masters S, et al. The B30.2 domain of pyrin, the Familial Mediterranean Fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci. 2006; 103:9982-7.

Livneh A, Langevitz P. Diagnostic and treatment concerns in familial mediterranean fever. Baillieres Best Pract Res Clin Rheumatol. 2000;14:47798.

Isik A, Koca SS, Ozturk A, et al. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:872-8.

Hanly JG, Fisk JD, McCurdy G, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2005;32:1459-66.

Martindale J, Smith J, Sutton CJ, et al. Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford). 2006;45:1288-93.

Ozen S.New interest in an old disease: Familial Mediterranean Fever. Clin Exp Rheumatol. 1999;17:745-9.

Aydemir Ö, Güvenir T, Küey L, ve ark. Hastane Anksiyete ve Depresyon Ölçeği Türkçe Formunun Geçerlik Güvenilirlik Çalışması. Türk Psikiyatri Dergisi. 1997;8:280-7.

Gencay-Can A, Can SS. Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. Rheumatol Int. 2012;32(1):27-31.

Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445-52.

Von Känel R, Hepp U, Kraemer B, et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res. 2007;41:744-52.

Bagci S, Toy B, Tuzun A, et al. Continuity of cytokine activation in patients with Familial Mediterranean Fever. Clin Rheumatol. 2004;23:333-7.

Simsek I, Pay S, Pekel A, et al. Serum proinflammatory cytokines directing T helper 1 polarization in patients with Familial Mediterranean Fever. Rheumatol Int. 2007;27:807-11.

Haznedaroglu S, Ozturk MA, Sancak B, et al. Serum interleukin 17 and interleukin 18 levels in Familial Mediterranean Fever. Clin Exp Rheumatol. 2007;23:77-80.

Erken E, Ozer HT, Gunesacar R. Plasma interleukin-10 and interleukin-12 levels in patients with Familial Mediterranean Fever. Rheumatol Int. 2006;26:862-4.

Duruoz MT, Unal C, Bingul DK, et al. Fatigue in Familial Mediterranean Fever and its relations with other clinical parameters. Rheumatology International. 2018;38:75-81.

Ozcakar L, Onat AM, Kaymak SU, et al. Selective serotonin reuptake inhibitors in Familial Mediterranean Fever: are we treating depression or inflammation? Rheumatol Int. 2005;25:319-20.

Onat AM, Oztürk MA, Ozçakar L, et al. Selective serotonin reuptake inhibitors reduce the attack frequency in Familial Mediterranean Fever. Tohoku J Exp Med. 2007;211:9-14.

Onat AM, Ozçakar L, Oztürk MA, et al. Plasma and platelet serotonin levels in Familial Mediterranean Fever. Clin Exp Rheumatol. 2007;25:16-20.

Deger SM, Ozturk MA, Demirag MD, et al. Health-related quality of life and its associations with mood condition in Familial Mediterranean Fever patients. Rheumatol Int. 2011;31(5):623-8.

Sahin S, Yalcin I, Senel S, et al. Assessment life quality of Familial Mediterranean Fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci. 2013;17:958-63.

Giese A, Kurucay M, Kilic L, et al. Quality of life in adult patients with Familial Mediterranean Fever living in Germany or Turkey compared to healthy subjects: a study evaluating the effect of disease severity and country of residence. Rheumatol Int. 2013;33:1713-9.

Giese A, Ornek A, Kilic L, et al. Anxiety and depression in adult patients with Familial Mediterranean Fever: a study comparing patients living in Germany and Turkey. Int J Rheum Dis. 2014;1756-185x.12297.

Kucuksahin O, Omma A, Ozdemirel AE, et al. Incidence of sleep disturbances in patients with Familial Mediterranean Fever and the relation of sleep quality with disease activity. Int J Rheum Dis. 2017.